The letter responds to comment on  Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model

We thank Dr. Tomoyuki Kawada for his comments on the clinicopathologic variables and gene expression profile (CP-GEP) model for melanoma risk stratification [1]. CP-GEP combines clinicopathologic (CP) variables and a gene expression profile (GEP) to identify primary cutaneous melanoma at high risk of metastasis [2,3]. We appreciate Dr. Kawada's remarks on the prognostic value of CP variables and concur that research on melanoma risk-stratification must continue.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research